These mechanisms and the ability of azaspiranes to normalise bone mineral density, prevent structural damage to joints and periarticular bone, and downregulate serum IL-6 levels (Bradbeer et al, 1996) without inducing myelotoxicity (King et al, 1991) suggest that these compounds may be effective against autoimmune disorders and diseases causing bone destruction.
Long-term (≥6 months) corticosteroid treatment is commonly prescribed in patients with glomerular disease, possibly causing bone loss both indirectly and directly, putting the patient at increased risk for fracture.
Depending on the disease causing the bone defects, along with the aforementioned biomaterials, other components can be added: various nanoparticles (magnetite, silver, or gold nanoparticles, zinc or titanium oxides, etc)., active agents, such as antibiotics, cytostatics, analgesics, and so forth, and targeting agents used in cancer treatment.
Oral exposure to aluminium can also affect the kidneys apart from causing bone and brain diseases at high levels.
Loss of teeth results in irreversible alveolar bone resorption, and untreated dental disease causes alveolar bone lysis that ultimately leads to loss of teeth.
Rheumatoid arthritis (RA) is a chronic autoimmune disease causing synovial inflammation, bone erosion, and cartilage destruction.
Rheumatoid arthritis (RA) is a chronic inflammatory disease causing cartilage and bone destruction in the joints.
Eventually I was referred to the aforementioned rheumatologist who explained I had an autoimmune disease that can cause bone fusing, heart disease, and chronic pain.
In humans, mutations leading to loss of function of this gene are associated with diseases causing sclerosing bone lesions and increased bone density, such as osteopoikilosis [ 39, 40].
